Comparison of non-vertebral fracture between minodronate and risedronate therapy in elderly female patients with Alzheimer disease

Journal of Musculoskeletal Neuronal Interactions

Volumn 13, Issue 3, 2013, Pages 308-314

  Sato, Y ^a   Honda, Y ^a   Iwamoto, J ^b   Amano, N ^c  

^a Mitate Hospital   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TEZUKAYAMA UNIVERSITY   (Japan)

Author keywords

Alzheimer disease; Bone mineral density; Hip fracture; Minodronate; Risedoronate

Indexed keywords

25 HYDROXYVITAMIN D; BONOTEO; CALCIUM; ERGOCALCIFEROL; MINODRONIC ACID; RISEDRONIC ACID; UNCLASSIFIED DRUG; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; ETIDRONIC ACID; IMIDAZOLE DERIVATIVE;

ABDOMINAL PAIN; AGED; ALZHEIMER DISEASE; ARTICLE; BONE DENSITY; COMPENSATORY HYPERPARATHYROIDISM; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; FALLING; FEMALE; FOLLOW UP; FOREARM FRACTURE; FRACTURE; GASTROINTESTINAL SYMPTOM; HEARTBURN; HIP FRACTURE; HUMAN; HYPERPARATHYROIDISM; MAJOR CLINICAL STUDY; NAUSEA; NONVERTEBRAL FRACTURE; PATIENT COMPLIANCE; PELVIS FRACTURE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; BODY MASS; COMPARATIVE STUDY; COMPLICATION; DRUG EFFECTS; FRACTURES, BONE; OSTEOPOROSIS;

ACCIDENTAL FALLS; AGED; ALZHEIMER DISEASE; BODY MASS INDEX; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; FRACTURES, BONE; HUMANS; IMIDAZOLES; OSTEOPOROSIS;

EID: 84886650691     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Johansson C, Skoog I. A population-based study on the association between dementia and hip fractures in 85-year olds. Aging (Milano) 1996;8:189-96.
2. Melton LJ III, Beard CM, Kokmen E, Atkinson EJ, O' Fallon WM. Fracture risk in patients with Alzheimer's disease. J Am Geriatr Soc 1994;42:614-9.
3. van Staa TP, Leufkens HG, Cooper C. Utility of medical and drug history in fracture risk prediction among men and women. Bone 2000;31:508-14.
4. Buchner DM, Larson EB. Falls and fractures in patients with Alzheimer-type dementia. JAMA 1987;257:1492-5.
5. Holmes J, House A. Psychiatric illness predicts poor outcome after surgery for hip fracture: a prospective cohort study. Psychol Med 2000;30:921-9.
6. Matsueda M, Ishii Y. The relationship between dementia score and ambulatory level after hip fracture in the elderly. Am J Orthop 2000;29:691-3.
7. Morrison RS, Siu AL. Mortality from pneumonia and hip fractures in patients with advanced dementia. JAMA 2000;284:2447-8.
8. Nightingale S, Holmes J, Mason J, House A. Psychiatric illness and mortality after hip fracture. Lancet 2001; 357:1264-5.
9. Sato Y, Asoh T, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in elderly women with Alzheimer's disease. Bone 1998;25:555-557.
10. Kipen E, Helme RD, Wark JD, Flicker L. Bone density, vitamin D nutrition, and parathyroid hormone levels in women with dementia. J Am Geriatr Soc1995;43:1088-91.
11. Loskutova N, Honea RA, Vidoni ED, Brooks WM, Burns JM. Bone density and brain atrophy in early Alzheimer's disease. J Alzheimers Dis 2009;18:777-85.
12. Loskutova N, Honea RA, Brooks WM, Burns JM. Reduced limbic and hypothalamic volumes correlate with bone density in early Alzheimer's disease. J Alzheimers Dis 2010;20:313-22.
13. Zhou R, Deng J, Zhang M, Zhou HD, Wang YJ. Associ ation between bone mineral density and the risk of Alzheimer's disease. J Alzheimers Dis 2011;24:101-8.
14. Fleisch H. Bisphophonate-preclinical. In: Fleisch H. editor. Bisphophonate in bone disease: from the Laboratory to the patient. New York: Academic Press: 2000 p. 27-66.
15. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296:235-42.
16. Mori H, Nisizawa Y, Tekatani Y, et al. A randomized controlled trial with ONO-5920 (minodronate/YM529) in Japanese patients with postmenopausal osteoporosis. J Bone Miner Res 2002;17(Suppl):S471.
17. Hagino H, Nishizawa Y, Sone T, et al. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone 2009; 44:1078-84.
18. Matsumoto T, Hagino H, Shiraki M, et al. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 2009;20:1429-37.
19. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report on the NINCDSADRADA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
20. Tamimi I, Ojea T, Sanchez-Siles JM, et al. Acetylcholinesterase inhibitors and the risk of hip fracture in Alzheimer's disease patients: a case-control study. J Bone Miner Res 2012;27:1518-27.
21. Ilić K, Obradović N, Vujasinović-Stupar N. The relationship among hypertension, antihypertensive medications, and osteoporosis: a narrative review. Calcif Tissue Int 2013;92:217-27.
22. Folstein MF, Folstein SF, McHugh PR. "Mini Mental State." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
23. Mahoney FI, Barthel DW. Functional evaluation: The Barthel index. Md St Med J 1965;14:61-5.
24. Komar L, Nieves J, Cosman F, Rubin A, Shen V, Lindsay R. Calcium homeostasis of an elderly population upon admission to a nursing home. J Am Geriatr Soc 1993; 41:1057-64.
25. Matsumoto C, Kushida K, Yamazaki K, Imose K, Inoue T. Metacarpal bone mass in normal and osteoporotic Japanese women using computed X-ray densitometry. Calcif Tissue Int1994:55:324-9.
26. Sato Y, Asoh T, Kaji M, Oizumi K. Benefical effect of intermittent cyclical etidronate therapy in hemiplegic patients following an acute stroke. J Bone Mineral Res 2000;15;2487-94.
27. Sato Y, Kaji M, Tsuru T, Oizumi K. Risk factors for hip fracture among elderly patients with Parkinson's disease. J Neurol Sci 2001;82:89-93.
28. Sato Y, Kanoko T, Yasuda H, Satoh K, Iwamoto J. Beneficial effect of etidronate therapy in immobilized hip fracture patients. Am J Phys Med & Rehabil 2004;83:298-303.
29. Matsumoto C, Kushida K, Sato Y. The second metacarpal bone density by microdensitometry method [in Japanese]. Seikeigeka 1992;43:1140-6.
30. Sato Y, Iwamoto J, Kanoko T, Satoh K. The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease. A randomized controlled trial. Arch Intern Med 2005;165:1737-42.
31. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls. A meta-analysis. JAMA 2004;291:1999-2006.
32. Tanaka M, Mori H, Kayasuga R, et al. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia. Bone 2008;43:894-900.
33. Yoshida Y, Moriya A, Kitamura K, et al. Responses of trabecular and cortical bone turnover and bone mass and strength to bisphosphonate YH529 in ovariohysterectomized beagles with calcium restriction. J Bone Miner Res 1998;13:1011-22.